Abnormal platelet activation in patients with type 2 diabetes mellitus

• Project/Area Number: 24591323
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Metabolomics
• Research Institution: Shiga University of Medical Science
• Principal Investigator: ARAKI Shin-ichi 滋賀医科大学, 医学部, 助教 (80378455)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 糖尿病 / 血小板活性 / 抗血小板薬 / アスピリン / アルブミン尿

Outline of Final Research Achievements

Prevention of cardiovascular disease is an important therapeutic goal in patients with type 2 diabetes. The aim of this study was to investigate the abnormal platelet activation, evaluated by the formation of spontaneous microaggregation of platelets (SMAP) and the expression of active GPIIb/IIIa and P-selectin on the surface of platelets in diabetic patients. First, we measured these index in 311 patients and continuously collected the annual clinical data and outcome. Second, we conducted an open label, single arm, uncontrolled trial of antiplatelet treatment with cilostazol as an alternative to aspirin in 23 Japanese patients with type 2 diabetes mellitus who had SMAP despite treatment with aspirin for at least 1 year. As results, cilostazol significantly attenuated the degree of the SMAP formation. Seventeen patients had a SMAP reduction of > 50% when compared with baseline values. Platelet expression of active GPIIb/IIIa and P-selectin was also attenuated by cilostazol.

Research Products

• [Journal Article] Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin. (2013)
  • Author(s): Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Kume S, Isshiki K, Araki H, Ugi S, Kawai H, Kashiwagi A, Uzu T, Maegawa H.
  • Journal Title: Diabetes Care Volume: 36(7) Issue: 7 Pages: e92-e93
  • DOI: 10.2337/dc12-2702
  • Peer Reviewed
• [Presentation] シロスタゾールは、2型糖尿病患者のアスピリン不応性自然誘発微小血小板凝集塊の形成を減弱させる (2013)
  • Author(s): 荒木 信一, 松野 浩之, 羽田 勝計, 古家 大祐, 柏木 厚典, 宇津 貴, 前川 聡
  • Organizer: 第56回日本糖尿病学会年次学術集会
  • Place of Presentation: 熊本